Thomas Frenzel

Summary

Affiliation: Bayer HealthCare AG
Country: Germany

Publications

  1. ncbi Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C
    Thomas Frenzel
    Bayer Schering Pharma, Berlin, Germany
    Invest Radiol 43:817-28. 2008
  2. ncbi Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand
    Martin A Sieber
    Research Diagnostic Imaging Bayer Schering Pharma AG, Berlin, Germany
    J Magn Reson Imaging 27:955-62. 2008
  3. ncbi Evaluating the role of zinc in the occurrence of fibrosis of the skin: a preclinical study
    Hubertus Pietsch
    Contrast Media Research, Bayer Schering Pharma AG, Berlin, Germany
    J Magn Reson Imaging 30:374-83. 2009
  4. ncbi Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents
    Hubertus Pietsch
    Bayer Schering Pharma AG Contrast, Media Research, Muellerstrasse 178, 13353, Berlin, Germany
    Eur Radiol 19:1417-24. 2009
  5. ncbi Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents
    Hubertus Pietsch
    TRG Diagnostic Imaging, Bayer Schering Pharma AG, Berlin, Germany
    Invest Radiol 44:226-33. 2009
  6. ncbi The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats
    Hubertus Pietsch
    Contrast Media Research, Bayer Schering Pharma AG, Berlin, Germany
    Invest Radiol 46:48-56. 2011
  7. ncbi A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media
    Martin A Sieber
    Bayer Schering Pharma AG, Berlin, Germany
    Invest Radiol 43:65-75. 2008
  8. ncbi Comparative studies on the efficacy of MRI contrast agents in MRA
    Hanns-Joachim Weinmann
    Research Laboratories, Schering AG, Berlin, Germany
    Acad Radiol 9:S135-6. 2002

Collaborators

Detail Information

Publications8

  1. ncbi Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C
    Thomas Frenzel
    Bayer Schering Pharma, Berlin, Germany
    Invest Radiol 43:817-28. 2008
    ..Assessment of the complex stability and Gd3+ dissociation rate of all marketed gadolinium-based MRI contrast agents (GBCA) in human serum at pH 7.4 and 37 degrees C...
  2. ncbi Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand
    Martin A Sieber
    Research Diagnostic Imaging Bayer Schering Pharma AG, Berlin, Germany
    J Magn Reson Imaging 27:955-62. 2008
    ..Using a dosing regimen to simulate the exposure seen in patients with severe renal impairment, we investigated the effect of excess ligand on Gd-deposition and the depletion of endogenous ions...
  3. ncbi Evaluating the role of zinc in the occurrence of fibrosis of the skin: a preclinical study
    Hubertus Pietsch
    Contrast Media Research, Bayer Schering Pharma AG, Berlin, Germany
    J Magn Reson Imaging 30:374-83. 2009
    ..The depletion of endogenous Zinc ions (Zn) caused by the administration of gadolinium-based contrast agents (GBCAs) has been suggested as a possible pathomechanism for nephrogenic systemic fibrosis (NSF)...
  4. ncbi Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents
    Hubertus Pietsch
    Bayer Schering Pharma AG Contrast, Media Research, Muellerstrasse 178, 13353, Berlin, Germany
    Eur Radiol 19:1417-24. 2009
    ..In summary, we observed a correlation between the complex stability of GBCAs and the amount of residual Gd in the skin up to a year after application of GBCAs...
  5. ncbi Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents
    Hubertus Pietsch
    TRG Diagnostic Imaging, Bayer Schering Pharma AG, Berlin, Germany
    Invest Radiol 44:226-33. 2009
    ..The aim of this study was to determine the impact of a prolonged circulation time of GBCAs caused by reduced renal clearance on the long-term retention of Gd in the skin of rats after administration of different GBCAs...
  6. ncbi The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats
    Hubertus Pietsch
    Contrast Media Research, Bayer Schering Pharma AG, Berlin, Germany
    Invest Radiol 46:48-56. 2011
    ..In addition, we evaluated whether an acute response to Gd exposure can initiate a process that results in fibrosis of the skin...
  7. ncbi A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media
    Martin A Sieber
    Bayer Schering Pharma AG, Berlin, Germany
    Invest Radiol 43:65-75. 2008
    ....
  8. ncbi Comparative studies on the efficacy of MRI contrast agents in MRA
    Hanns-Joachim Weinmann
    Research Laboratories, Schering AG, Berlin, Germany
    Acad Radiol 9:S135-6. 2002